Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of QX005N injection in adults with prurigo nodularis
CTR20223174Phase 2Completed
- Sponsor
- Quxin Biopharmaceutical
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QX005N in prurigo nodularis (PN) (4 arms), sponsored by Quxin Biopharmaceutical. Primary endpoint: Proportion of subjects with WI-NRS weekly mean decrease ≥4 points at Week 16. Started Dec 2022; status: completed.
02
Drugs
QX005N
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on CTR20223174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223174.